Andre Vivan da Silva – Country Manager, GSK Brazil
After a successful international career, Andre Vivan da Silva recently returned to his native Brazil to become GSK’s country manager. He explains the importance of vaccination, in Brazil, and HIV…
We are one of the world leaders in the creation of therapeutic solutions that help improve people’s quality of life by working on the development of innovative products in the fields of prescription drugs, vaccines and health care.
We have a significant global presence with business activities in more than 150 countries, a network of 84 production units in 36 countries and major R&D centers in the UK, USA, Spain, Belgium and China. In Brazil, we have factories in the states of São Paulo and Rio de Janeiro.
Contact:
Address: Estrada dos Bandeirantes 8464
Rio de Janeiro
RJ CEP 22783-110 or CNPJ 33.247743/0001-10
Tel.: +55 (800) 701 22 33
Website: https://br.gsk.com/
After a successful international career, Andre Vivan da Silva recently returned to his native Brazil to become GSK’s country manager. He explains the importance of vaccination, in Brazil, and HIV…
Alexei Kolchin, general manager of GSK Brazil, discusses adapting to Brazil, having previously held the equivalent role in Russia, the Brazilian affiliate’s contribution to GSK’s global growth, and its embrace…
You’ve made some bold moves in your career – from the head of vaccines in Latin America, followed by stints in Colombia, Puerto Rico, and finally Brazil. What brought you…
Much has changed at Bomi since we last met in 2007. At that time, you were launching your new facilities, with 72,000 square metres of built area, 14 metres free…
Two days ago, the Ministry of Health released an article stating that chronic diseases now account for 70% of all deaths in Brazil, and welcoming suggestions for the national plan…
Your position unites two somewhat incongruous titles – Director of Sustainability, and New Business. How did this come to be, and what if any overlap is there between these two…
You came to Boehringer Ingelheim in 2009 – what are some of the most exciting milestones and achievements you have presided over during this time? Looking back on almost three…
When we met Servier Brazil five years ago the company had major ambitions: ‘grow more than 10% for the five following years’. How have these expectations turned out to be?…
Mr. Mauricio, you’ve mentioned that Brazil is a different kind of market for Octapharma, one strongly based on price, and that because of this it’s hard to add value. Could…
When we were in Australia, we met with the “star scientist” Ian Frazier, who was Australian of the Year in 2009 for his co-discovery of Merck’s Gardasil. Or Singulair, which…
In an exclusive interview, Otto Philipp Braun, part of medtech giant B. Braun’s family dynasty, discusses his achievements as MD in Brazil, the company’s operations in the country and globally, as…
When we met you in 2007, as the head of the former Igefarma, the company was undergoing a transition – from branded generics into dermocosmetics and women’s health. But since…
Rogerio, you were one of the people responsible for integrating two well-established companies in the Brazilian market with the acquisition of Exel by DHL in late 2005. How challenging was…
You have 25 years of experience in the Brazilian pharmaceutical industry, witnessing the major transformations of this market and the fast emergence of generics. Regarding your background and experience at…
When we spoke with Mr. Barbano at ANVISA, he mentioned RDC 55/10 and his hopes that it will do for the biologics market what the generics law of 1999 did…
See our Cookie Privacy Policy Here
